91 related articles for article (PubMed ID: 15726649)
61. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
Bishop KN; Holmes RK; Malim MH
J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
[TBL] [Abstract][Full Text] [Related]
62. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells.
Chen K; Huang J; Zhang C; Huang S; Nunnari G; Wang FX; Tong X; Gao L; Nikisher K; Zhang H
J Virol; 2006 Aug; 80(15):7645-57. PubMed ID: 16840343
[TBL] [Abstract][Full Text] [Related]
63. APOBEC3G and HIV-1: strike and counterstrike.
Soros VB; Greene WC
Curr Infect Dis Rep; 2006 Jun; 8(4):317-23. PubMed ID: 16822376
[TBL] [Abstract][Full Text] [Related]
64. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies.
Wichroski MJ; Robb GB; Rana TM
PLoS Pathog; 2006 May; 2(5):e41. PubMed ID: 16699599
[TBL] [Abstract][Full Text] [Related]
65. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
[TBL] [Abstract][Full Text] [Related]
66. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.
Peng G; Lei KJ; Jin W; Greenwell-Wild T; Wahl SM
J Exp Med; 2006 Jan; 203(1):41-6. PubMed ID: 16418394
[TBL] [Abstract][Full Text] [Related]
67. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids.
Wieland SF; Eustaquio A; Whitten-Bauer C; Boyd B; Chisari FV
Proc Natl Acad Sci U S A; 2005 Jul; 102(28):9913-7. PubMed ID: 15994231
[TBL] [Abstract][Full Text] [Related]
68. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
Langlois MA; Beale RC; Conticello SG; Neuberger MS
Nucleic Acids Res; 2005; 33(6):1913-23. PubMed ID: 15809227
[TBL] [Abstract][Full Text] [Related]
69. APOBEC family proteins: novel antiviral innate immunity.
Takaori-Kondo A
Int J Hematol; 2006 Apr; 83(3):213-6. PubMed ID: 16720550
[TBL] [Abstract][Full Text] [Related]
70. Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus.
Bonvin M; Greeve J
Curr Opin Infect Dis; 2008 Jun; 21(3):298-303. PubMed ID: 18448976
[TBL] [Abstract][Full Text] [Related]
71. G to A hypermutation of hepatitis B virus.
Noguchi C; Ishino H; Tsuge M; Fujimoto Y; Imamura M; Takahashi S; Chayama K
Hepatology; 2005 Mar; 41(3):626-33. PubMed ID: 15726649
[TBL] [Abstract][Full Text] [Related]
72. Dual effect of APOBEC3G on Hepatitis B virus.
Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Fujimoto Y; Ochi H; Abe H; Maekawa T; Yatsuji H; Shirakawa K; Takaori-Kondo A; Chayama K
J Gen Virol; 2007 Feb; 88(Pt 2):432-440. PubMed ID: 17251560
[TBL] [Abstract][Full Text] [Related]
73. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo.
Suspène R; Guétard D; Henry M; Sommer P; Wain-Hobson S; Vartanian JP
Proc Natl Acad Sci U S A; 2005 Jun; 102(23):8321-6. PubMed ID: 15919829
[TBL] [Abstract][Full Text] [Related]
74. N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication.
Lei YC; Tian YJ; Ding HH; Wang BJ; Yang Y; Hao YH; Zhao XP; Lu MJ; Gong FL; Yang DL
World J Gastroenterol; 2006 Dec; 12(46):7488-96. PubMed ID: 17167839
[TBL] [Abstract][Full Text] [Related]
75.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
76.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
